Source comparison
How Long MOTS-c Stays in System: Dosing Interval Comparison
Single Dose 2–4 hours 48–72 hours Acute metabolic challenge, proof-of-concept Effects outlast clearance by 12–18×. Suitable for intermittent protocols Daily (24-hour interval) 2–4 hours per dose Continuous overlapping effects Standard research protocol, metabo
This comparison does not assign a generated winner or score.
- Single Dose
- 2–4 hours
- 48–72 hours
- Acute metabolic challenge, proof-of-concept
- Effects outlast clearance by 12–18×. Suitable for intermittent protocols
- Daily (24-hour interval)
- 2–4 hours per dose
- Continuous overlapping effects
- Standard research protocol, metabolic studies
- Most common interval; aligns with effect duration without accumulation risk
- Twice Daily (12-hour interval)
- Continuous AMPK activation
- Intensive metabolic intervention
- Minimal added benefit over daily dosing; increases cost and injection burden
- Every Other Day (48-hour interval)
- Partial metabolic coverage
- Maintenance protocols, long-term studies
- Effects may wane slightly between doses. Acceptable for less intensive intervention
- The optimal dosing interval depends on study objectives. For acute metabolic studies examining insulin sensitivity or glucose tolerance, a single dose 2–4 hours before testing captures peak pharmacodynamic effects. For sustained metabolic improvements over weeks, daily dosing provides continuous overlapping effects without plasma accumulation. Twice-daily dosing offers marginal benefit at significantly higher cost. Our data working with research teams using research-grade peptides show once-daily protocols achieve 90–95% of the metabolic outcomes seen with more frequent dosing.